<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">170</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2016-15-3-46-53</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL OBSERVATIONS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Secondary porphyrinurias</article-title><trans-title-group xml:lang="ru"><trans-title>Вторичные порфиринурии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fedorova</surname><given-names>Darya V.</given-names></name><name xml:lang="ru"><surname>Федорова</surname><given-names>Дарья Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>darya.v.fedorova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khomyakova</surname><given-names>Svetlana P.</given-names></name><name xml:lang="ru"><surname>Хомякова</surname><given-names>Светлана Прокофьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>xomikova.cv@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kozlovskiy</surname><given-names>Andrey S.</given-names></name><name xml:lang="ru"><surname>Козловский</surname><given-names>Андрей Станиславович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>andey.s.kozlovsky@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Surin</surname><given-names>Vadim L.</given-names></name><name xml:lang="ru"><surname>Сурин</surname><given-names>Вадим Леонидович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vadsurin@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dmitry Rogachev Federal Research Centre of Paediatric Haematology, Oncology and Immunology, Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian Paediatric Clinical Hospital, Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">Российская детская клиническая больница Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Haematologic Research Centre, Ministry of Health the Russian Federation</institution></aff><aff><institution xml:lang="ru">Гематологический научный центр Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-09-19" publication-format="electronic"><day>19</day><month>09</month><year>2016</year></pub-date><volume>15</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>46</fpage><lpage>53</lpage><history><date date-type="received" iso-8601-date="2018-09-19"><day>19</day><month>09</month><year>2018</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/170">https://hemoncim.com/jour/article/view/170</self-uri><abstract xml:lang="en"><p>The article reviews literature data dealing with secondary metabolic disorders of heme precursors and their clinical significance in the context of differential diagnosis with « genuine » hereditary porphyrias. Secondary disorders of porphyrin metabolism are an insufficiently studied problem. As has been acknowledged, accumulation of copro- and uroporphirins itself cannot cause neurological symptoms similar to such in acute hepatic porphyrias. Nevertheless, the bulk of literature contains descriptions of patients with acute-onset polyneuropathies or encephalopathies, in whom coproporphyrinuria was found. The authors put emphasis on the importance of ruling out acute porphyrias in patients with combinations of polyneuropathy and abdominal pain syndrome, photosensitivity, autonomic dysfunction. Also, the article presents four authentic clinical observations of paediatric and adolescent patients, in whom acute porphyria was suspected on the basis of the clinical picture. Examination, however, revealed only a moderate increase of excretion of late heme precursors. Therefore, the diagnosis of acute hepatic porphyria was not confirmed. On the other hand, the genesis of secondary porphyrinuria in such patients, as well as the causative relations between neurological symptoms and disorders of porphyrin metabolism remain unclear.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="ru"><kwd>вторичные порфиринурии</kwd><kwd>дети</kwd><kwd>диагностика</kwd><kwd>копропорфиринурия</kwd><kwd>метаболизм гема</kwd><kwd>острые порфирии</kwd><kwd>полинейропатия</kwd><kwd>психоневрологическая симптоматика</kwd><kwd>secondary porphyrinuria</kwd><kwd>children</kwd><kwd>diagnosis</kwd><kwd>coproporphyrinuria</kwd><kwd>heme metabolism</kwd><kwd>acute porphyrias</kwd><kwd>polyneuropathy</kwd><kwd>psychoneurological symptoms</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kleingardner JG, Bren KL. Biological significance and applications of heme c proteins and peptides. Acc Chem Res. 2015;48(7):1845-52.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Besur S, Hou W, Schmeltzer P, Bonkovsky HL. Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites. 2014;4(4): 977-1006.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Fujiwara T, Harigae H. Biology of heme in mammalian erythroid cells and related disorders. Biomed Res Int. 2015;2015:278536.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Herrick AL, McColl KE. Acute intermittent porphyria. Best Pract Res Clin Gastroenterol. 2005;19(2):235-49.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375(9718):924-37.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Karim Z, Lyoumi S, Nicolas G, Deybach JC, Gouya L, Puy H. Porphyrias: a 2015 update. Clin Res Hepatol Gastroenterol. 2015;39(4):412-25.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Besur S, Schmeltzer P, Bonkovsky HL. Acute porphyrias. J Emerg Med. 2015;49(3):305-12.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bissell DM, Wang B. Acute hepatic porphyria. J Clin Transl Hepatol. 2015;3(1): 17-26.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Stein P, Badminton M, Barth J, Rees D, Stewart MF; British and Irish Porphyria Network. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Ann Clin Biochem. 2013;50(Pt 3):217-23.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Lin CS, Lee MJ, Park SB, Kiernan MC. Purple pigments: the pathophysiology of acute porphyric neuropathy. Clin Neurophysiol. 2011;122(12):2336-44.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Liu LU, Phillips J, Bonkovsky H. Porphyria cutanea tarda, type II[Updated 2013 Aug 22]. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al, eds. GeneReviews® [Internet]. Seattle (WA):University of Washington, Seattle; 1993-2016 [cited 2016 Mar 30]. Avaible at: http://www.ncbi.nlm.gov/ books/NBK143129.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Liu LU, Phillips J, Bonkovsky H. Hepatoerythropoietic porphyria [Updated 2013 Oct 31]. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al, eds. GeneReviews® [Internet]. Seattle (WA):University of Washington, Seattle;1993-2016 [cited 2016 Mar 30]. Avaible at: http://www.ncbi.nlm.gov/ books/NBK169003.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Ventura P, Cappellini MD, Rocchi E. The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine. Intern Emerg Med. 2009;4(4):297-308.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Bissell DM, Lai JC, Meister RK, Blanc PD. Role of delta-aminolevulinic acid in the symptoms of acute porphyria. Am J Med. 2015;128(3):313-7.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Bonkovsky HL, Guo JT, Hou W, Li T, Narang T, Thapar M. Porphyrin and heme metabolism and the porphyrias. Compr Physiol. 2013;3(1):365-401.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Pischik E, Kazakov V, Kauppinen R. Is screening for urinary porphobilinogen useful among patients with acute polyneuropathy or encephalopathy? J Neurol. 2008;255(7):974-9.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Hift R, Meissner P. Miscellaneous abnormalities in porphyrin production and disposal. In: Kadish KM, Smith KM, Guilard R, eds. The porphyrin handbook. San Diego: Elsevier Science, 2003;151-65.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Bonkovsky HL, Barnard GF. Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. Semin Liver Dis. 1998;18(1):57-65.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Lamon JM. Clinical aspects of porphyrin measurement, other than lead poisoning. Clin Chem. 1977;23(2, Pt. 1):260-3.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Ochiai T, Morishima T, Kondo M. Symptomatic porphyria secondary to hepatocellular carcinoma. Br J Dermatol. 1997;136(1):129-31.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Doss MO, Kühnel A, Gross U. Alcohol and porphyrin metabolism. Alcohol Alcohol. 2000;35(2):109-25.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Akshatha LN, Rukmini MS, Shenoy MT, P SR, B P. Lead poisoning mimicking acute porphyria! J Clin Diagn Res. 2014;8(12):CD01-2.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Andrade VM, Mateus ML, Batoréu MC, Aschner M, Marreilha dos Santos AP. Lead, arsenic, and manganese metal mixture exposures: focus on biomarkers of effect. Biol Trace Elem Res. 2015;166(1):13-23.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Wang L, Angley MT, Gerber JP, Sorich MJ. A review of candidate urinary biomarkers for autism spectrum disorder. Biomarkers. 2011;16(7):537-52.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Heyer NJ, Echeverria D, Woods JS. Disordered porphyrin metabolism: a potential biological marker for autism risk assessment. Autism Res. 2012;5(2):84-92.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Shandley K, Austin DW, Bhowmik JL. Are urinary porphyrins a valid diagnostic biomarker of autism spectrum disorder? Autism Res. 2014;7(5):535-42.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Macedoni-Luksic M, Gosar D, Bj0rklund G, Orazem J, Kodric J, Lesnik-Musek P, et al. Levels of metals in the blood and specific porphyrins in the urine in children with autism spectrum disorders. Biol Trace Elem Res. 2015;163(1-2):2-10.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Markova A, Lester J, Wang J, Robinson-Bostom L. Diagnosis of common dermo-pathies in dialysis patients: a review and update. Semin Dial. 2012;25(4):408-18.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Oberndorfer S, Hitzenberger P, Gruber W, Seidel J, Urbanits S, Doss M, et al. Secondary coproporphyrinuria in a patient with the full clinical picture of a hereditary acute hepatic porphyria. A misleading clinical and biochemical course. J Neurol. 2002;249(9):1325-26.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ahle G, Wierzba S, Haupts M, König M, Gehlen W. Acute left hemispheric syndrome with cortical lesions in a patient with secondary porphyrinuria. J Neurol. 2005;252(8):983-4.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Siegesmund M, van Tuyll van Serooskerken AM, Poblete-Gutiérrez P, Frank J. The acute hepatic porphyrias: current status and future challenges. Best Pract Res Clin Gastroenterol. 2010;24(5):593-605.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Anyaegbu E, Goodman M, Ahn SY, Thangarajh M, Wong M, Shinawi M. Acute intermittent porphyria: a diagnostic challenge. J Child Neurol. 2012;27(7):917-21.</mixed-citation></ref></ref-list></back></article>
